In addition, flow cytometry detection of CD14 showed that compared with 2F5-treatment group, CD14-positive APL cells treated with 2F5 combined NAC were decreased significantly (Fig. S6). The gene discussed is CD14; the disease is acute promyelocytic leukemia.